key: cord-0980811-j0ytd3hw
authors: Nieto, Guillermo Valenzuela; Jara, Ronald; Watterson, Daniel; Modhiran, Naphak; Amarilla, Alberto A; Himelreichs, Johanna; Khromykh, Alexander A.; Salinas, Constanza; Pinto, Teresa; Cheuquemilla, Yorka; Margolles, Yago; González del Rey, Natalia López; Miranda-Chacon, Zaray; Cuevas, Alexei; Berking, Anne; Deride, Camila; González-Moraga, Sebastián; Mancilla, Héctor; Maturana, Daniel; Langer, Andreas; Toledo, Juan Pablo; Müller, Ananda; Uberti, Benjamín; Krall, Paola; Ehrenfeld, Pamela; Blesa, Javier; Chana-Cuevas, Pedro; Rehren, German; Schwefel, David; Fernandez, Luis Ángel; Rojas-Fernandez, Alejandro
title: Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity Nanobody
date: 2020-09-03
journal: bioRxiv
DOI: 10.1101/2020.06.09.137935
sha: 2fdde1b5e8bbe86aa1ea38b03914005cbfb7bfb3
doc_id: 980811
cord_uid: j0ytd3hw

Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to reduce the burden placed on health systems, the situation remains critical. Effective diagnosis, treatment, and prophylactic measures are urgently required to meet global demand: recombinant antibodies fulfill these requirements and have marked clinical potential. Here, we describe the fast-tracked development of an alpaca Nanobody specific for the receptor-binding-domain (RBD) of the SARS-CoV-2 Spike protein with therapeutic potential applicability. We present a rapid method for nanobody isolation that includes an optimized immunization regimen coupled with VHH library E. coli surface display, which allows single-step selection of high-affinity nanobodies using a simple density gradient centrifugation of the bacterial library. The selected single and monomeric Nanobody, W25, binds to the SARS-CoV-2 S RBD with sub-nanomolar affinity and efficiently competes with ACE-2 receptor binding. Furthermore, W25 potently neutralizes SARS-CoV-2 wild type and the D614G variant with IC50 values in the nanomolar range, demonstrating its potential as antiviral agent.

Severe clinical courses of pandemic coronavirus disease 2019 , the illness caused by SARS-CoV-2 infection, involve pneumonia and multiple organ dysfunction, and constitute an unprecedented threat to health and economy worldwide (1) (2) (3) (4) . Currently, there are no vaccines or drugs to effectively contain the pandemic. In order to avoid the collapse of healthcare systems, non-pharmaceutical public health measures such as social distancing, border closures, and lockdowns have been enforced globally (5, 6) . Genetic studies determined that the pathogen responsible for this outbreak belongs to the Coronaviridae family, genus Beta-coronavirus, subgenus sarbecovirus (7) . It has high sequence homology with the bat coronavirus RaTG13, indicating that the novel virus may have originated in bats and subsequently jumped to humans, probably via a yet unidentified intermediate animal host (8) .

The positive sense SARS-CoV-2 RNA genome contains 29903 nucleotides, including 12 open reading frames (ORFs) coding for the replicase ORF1ab polyproteins, Spike, Envelope, Membrane and Nucleocapsid structural proteins, and several accessory proteins (9, 10) . The Spike protein on the virion surface is responsible for attachment to, and invasion of host cells (11) .

Spike is a highly glycosylated trimeric class I fusion protein and contains two subunits, S1 and S2 (12) . Similar to SARS-CoV, Angiotensin-converting-enzyme 2 (ACE2) appears to be the molecular entryway to the host, since SARS-CoV-2 S binds to this receptor (12) (13) (14) (15) . Moreover, the presence of the ACE2 receptor has been confirmed in a variety of human tissues that are related to clinical manifestations of COVID-19 (16) (17) (18) (19) .

CryoEM studies showed that SARS-CoV-2 Spike exhibits a metastable pre-fusion conformation, where the RBD within S1 performs hinge-like movements between "down"-and "up"-positions relative to the remainder of the S protein. Only in the "up"-position, RBD residues responsible for binding to the ACE2 receptor on the host cell surface are exposed. After attachment, proteolytic processing and S1 shedding, the S2 subunit undergoes substantial conformational rearrangements to a stable post-fusion conformation, concomitant with membrane fusion and invasion of the host cell (20, 21) . Host TMPRRS2 serine proteases seem to be responsible for this proteolytic priming, attacking a furin-like cleavage site situated in between the S1 and S2 subunits of the Spike protein (22, 23) .

Recent studies highlighted the emergence of the Spike protein variant D614G, which has become the dominant SARS-CoV-2 pandemic strain (24) . This variant seems to replicate better in cell culture, but it is disputed if the mutation results in increased viral load or infectivity in humans (25, 26) . Interestingly, the S protein residue 614 is located in the interface between adjacent S protomers, and it has been hypothesized that amino acid exchange to glycine stabilizes the trimeric Spike protein architecture (27) Accordingly, the D614G variant exhibits less S1 subunit shedding and improved Spike protein incorporation into virions (28) . However, the mutation does not influence receptor binding or antibody neutralization, and seems not to be associated with worse clinical outcome (29, 30) Altogether, the central role of the Spike glycoprotein in the virus lifecycle highlights the importance of this protein as a target for the development of therapies such as neutralizing antibodies and vaccines (31) (32) (33) (34) (35) . In this sense, isolation of specific Spike protein antibodies can be instrumental in the development of effective diagnostic and therapeutic tools (36) (37) (38) (39) (40) .

Some naturally occurring antibodies that lack light chains (heavy-chain only antibody, HCAb) are known as single-domain antibodies. They are derivates of IgG and occur in the entire camelidae family (41) . The camelidae family consists of camels, dromedaries, llamas, vicuñas, guanaco, and alpacas (42) . The antigen-binding fragment of an HCAb contains a single variable heavy homodimer (VHH) domain consisting of 3 hypervariable regions. An isolated VHH domain is also referred to as a Nanobody. Nanobodies can be used as therapeutic bullets for instance, against tumors, pathogens, and chronic diseases (43) (44) (45) . Nanobodies are in general more stable than conventional antibodies and, unlike classical antibodies, can be efficiently produced in prokaryotic expression systems. In fact, several milligrams can be produced from one liter of culture (43, (46) (47) (48) (49) , offering a means to rapidly and economically produce therapeutic biologics at large scale.

Nanobodies derived from camelid HCAbs are obtained after immunization with the target protein plus adjuvant. Our platform has developed an improved procedure to produce Nanobodies using alpacas as the donor species. To obtain the genetic sequences of target-specific Nanobodies produced after immunization, peripheral blood B-lymphocytes are isolated to obtain total RNA, followed by cDNA preparation to finally amplify the Nanobody region (50) . The cDNA fragment encoding the Nanobody is as short as 360 nt, and up to ~ 3x10 6 single clones can be obtained from 120 mL blood in a safe and harmless procedure for our alpacas. Afterward, a bacterial display system is applied to rapidly clone the full single Nanobodies. Here, we make use of the bacterial display system to develop a fast, inexpensive and simple density gradient method for Nanobody selection, by which we identified a Nanobody against SARS-CoV-2 with strong binding and neutralizing activity.

We developed a method to fast-track Nanobody selection from alpacas and use the approach to obtain a Nanobody against the Spike protein of SARS-CoV-2 in only few weeks. We used lyophilized Spike protein produced in a baculovirus expression system as antigen. Prior to immunization, antigen integrity was tested by SDS-Page and Coomassie staining ( Figure 1a) .

Then, an alpaca (Figure 1b) was immunized twice over 14 days with 100 µg of the full Spike protein and adjuvant. The animal´s health was monitored throughout the study period by clinical examination, hematology analysis, and serum biochemistry. The immune response of the alpaca´s serum before immunization revealed a fortunate basal cross-reaction against the Spike protein, and after the second immunization, we observed a significant increase of antigen specific IgG antibodies in the alpaca´s serum. This analysis was done in a rapid qualitative manner by Dot blot analysis, immobilizing the epitope to a nitrocellulose membrane and using alpaca serum as a source of primary antibodies (Figure 1c) . We also detected an ~ 5-fold increment of IgG antibodies against Spike protein in the post-immunization serum by ELISA (Figure 1d ). Our method for Nanobody isolation is based on the bacterial display system, a strategy that takes advantage of the high transformation efficiency of E. coli and avoids the need for bacteriophage infections or shuttling into yeast cells for surface display of the Nanobodies (51) . Importantly, this Nanobody display system can drive the specific adhesion of E. coli bacteria to abiotic and cellular surfaces with the cognate antigen (52, 53) . Thus, we constructed a bacterial display library with a complexity of 2.3 x10 6 independent clones by electroporation of E. coli DH10B-T1R strain (53) (54) (55) (see Materials and Methods).

We applied a novel procedure for the selection of Nanobodies based on a simple Ficoll density gradient, an inexpensive reagent available all around the world used for blood fragmentation. We were inspired by the main observation that red cells accumulate at the bottom of the Ficoll density gradient, while PBMCs stay in the upper fraction. Using conventional NHS-activated sepharose beads in a Ficoll gradient, we found that the density of the beads was sufficient to precipitate to the bottom of a 15 mL tube. Furthermore, the same assay was performed with free bacteria, and as expected, the bacteria remained on top of the gradient. In the bacterial display system, a single Nanobody clone is expressed by each bacterium of the library (51) . E. coli bacteria express intimin-Nanobody protein fusions that anchor in the outer membrane upon IPTG-induction and expose the functional Nanobody to the extracellular milieu for antigen recognition. These intimin-Nanobody fusions also contain a common epitope (myc-tag) at the C-terminus for immunodetection (54) . Therefore, the bacteria expressing specific Nanobodies on their surface would bind NHS-beads coated with the protein of interest (i.e. SARS-CoV-2 S) and migrate all the way through to the bottom of the Ficoll density gradient, leaving unbound bacteria in the upper fraction ( Figure 1e ). Indeed, we demonstrated that specific Nanobodies from a bacterial display library are rapidly selected with our protocol, using common, inexpensive reagents and a conventional centrifuge. A full description is provided in the Materials and Methods section.

We optimized conditions to extract the intimin-Nanobody fusions from the bacterial outer membrane and used these protein extracts directly for assaying the binding to the Spike protein applying two different methods, dot blot analysis and high-content microscopy. After Nanobody selection using our simple Ficoll-based density gradient protocol, we obtained ~ 1000 colonies on LB-agar plates from the sepharose-antigen coated fraction. 100 colonies were analyzed of which 30 showed a high affinity for Spike. The bacteria were inoculated in liquid LB media and the expression of intimin-Nanobodies of the single clones was induced. Bacterial pellets were lysed under optimized conditions and the extract was used as a source of Nanobodies for the second binding screening. For dot blot analysis, a negative control of an unrelated protein was applied adjacent to the same amount of full-length Spike protein on the nitrocellulose strips. Single Dot blot strip tests were incubated with the bacterial extracts containing Nanobodies. Sequential incubation with mouse anti-myc antibody and an anti-mouse HRP-conjugate unveiled nanobodies binding to Spike. Of the first 100 clones, we focused on two Nanobodies that displayed a strong signal for full-length Spike in the Dot blot analysis (W23 and W25, Figure 2a ). Additionally, we used high content microscopy as a second confirmation method. For this purpose, a single 10 cmplate was transfected with a Spike-GFP vector for 24h and further the cells were seeded onto 96 well-plates. After 24 hours, the cells were fixed, permeabilized, and individual extracts of our 100 selected bacterial display clones were added as a source of Nanobodies. A mouse anti-myc antibody and an anti-mouse Alexa647 secondary antibody was used for immunofluorescence detection. HeLa cells had a transfection efficiency of ~20%. In this case, a low transfection rate is desired, because it allows us to evaluate unspecific binding to un-transfected cells in the same image. Consistent with the Dot blot analysis, the W23 and W25 Nanobodies bound to the Spike-GFP expressed in human cells (Figure 2b ). We observed co-localization of W23 and W25 to Spike-GFP, while no co-localization was observed with negative control extracts ( Figure 2b ). We also observed that W25 does not bind to the nucleoprotein of SARS-CoV-2 tagged to a GFP protein (Supplemental Figure 1b) confirming that W25 binds specifically to Spike and not to GFP.

The selected clones were sequenced and the alignment of the amino acid sequences showed a high similarity between the two Nanobodies, CDR3 was identical, suggesting that the two Nanobodies are members of the same family and were most likely generated from a common origin during the Alpaca´s immunoreaction against the Spike protein ( Figure 2c ). In conclusion, we developed a method that rapidly performs secondary screening selection of Nanobodies, using bacterial extracts from selected clones of the bacterial display library, using either conventional biochemical methods such as dot blot analysis, or high content microscopy immunofluorescencebased assays.

W25 was subsequently cloned into the pHen6 vector for periplasmic bacterial expression, and large amounts of recombinant W25 Nanobody were obtained ( Figure 2d ). The purified W25 Nanobody was used for immunofluorescence of HeLa cells transiently transfected with an S-GFP vector and specifically recognized the Spike-GFP in a sensitive manner (Figure 2e ), given that we observed co-localization of Spike-GFP and W25 to membrane protrusions in HeLa cells ( Figure   2e ). Thus, our experiment suggests the W25 Nanobody is applicable as a measure for the direct diagnosis of infected cells by immunofluorescence. Furthermore, we covalently labelled W25 to Horseradish Peroxidase (HRP) and performed direct ELISA assays using immobilized full-length Spike protein (Figure 2f ) or RBD only ( Figure 2g ). In both cases, W25 was able to recognize in an efficiently and sensitivemanner the viral proteins immobilized on the ELISA plate. Due to the high levels of expression and effective conjugation to HRP, the Nanobody W25 will be a convenient tool for the development of diagnostic approaches based on direct antigen detection. Furthermore, the efficient binding to RBD might indicate SARS-CoV-2 neutralization activity.

We further characterized the direct interaction between the Spike RBD and the W25 nanobody by pulldown assays, employing recombinant RBD protein or BSA as a control. Proteins were covalently immobilized on NHS-sepharose beads, and the binding of W25 to RBD and control beads was tested. We showed that the selected W25 Nanobody binds to RBD (Figure 3a) confirming previous ELISA results. To further study the interaction of W25 with S RBD, we first used thermal shift assays. We demonstrated integrity of the individual RBD and Nanobody preparations using a label-free Tycho measurement, yielding inflection temperatures of protein unfolding (Ti) of 52.4°C and 57.9°C, proving high thermal stability. Mixing the RBD domain with the nanobody, followed by the same measurement, led to a shift to higher unfolding inflection temperature of ~14°C, strongly indicative of tight interaction between the RBD and Nanobody Spike RBD. We labelled W25 with a florescent dye and generated and stable complex with RBD at a very low concentration of 1 nM W25 and 2 nM RBD. Increasing amounts of ACE2 were added, and dissociation of W25 was determined by thermophoresis. We observed an effective competition between W25 and ACE2 for RBD, where the ACE2 concentration to reach halfmaximal W25-dissociation (EC50) was determined to be 33 nM ± 9 nM (Figure 3d, e) . These results indicate that the binding affinity of the Nanobody W25 for RBD is considerably higher than that of ACE2, and suggest a direct competition for RBD interface residues between W25 and ACE2.

Next, we investigated the neutralization ability of W25 against two clinical isolates of SARS-CoV2 variants, respectively. As expected, no inhibition was observed for the MERS-specific VHH-55.

Thus, W25 represents a potent neutralizing monomeric Nanobody against SARS-CoV-2, with improved activity relative to other described HCAbs, and is able to inhibit the predominant circulating virus strain containing the Spike protein D614G mutation (Figure 3f -i).

Currently, selection of Nanobodies from bacterial display is performed by affinity purification based on magnetic beads binding the labelled antigen or by FACS Sorter or selection on cells transfected with the antigen (55) . Here, we describe a novel simple method for the selection of Nanobodies from E. coli bacterial display libraries. Our method requires only conventional laboratory instruments and an inexpensive Ficoll gradient for the selection of Nanobodies from a highly complex and diverse bacterial library. The success rate depends on the immune response of the alpaca to the epitope and by prior undetermined exposure to cross-reactive camelid coronaviruses (56) (57) (58) . Nevertheless, here we have shown a successful example based on an immunization program of two weeks duration and 100 analyzed clones resulting in the selection of 30 Nanobodies with high affinity for the antigen; thus, our method can accelerate the identification of Nanobodies, enabling, for example, the generation of diagnostic and potentially therapeutic measures against Covid-19 and other infectious and emergent viruses.

The medical, social, and economic consequences of COVID-19 impact the lives of everyone on the planet and while vaccines and effective therapies are not available, sensitive diagnostic tools are urgently needed. Currently, convalescent plasma transfusion has been applied as an emergency treatment for COVID-19, aiming to enhance the immune response of the patients (59, 60) . In the late phase of disease progression, an inflammatory cytokine storm has been reported.

Antibody administration at this stage by convalescent plasma transfusion is under discussion, especially for critically ill patients (61) . Also additional efforts have been done for the generation and clinical implementation of hyperimmune equine serum therapy approaches (62) . Nanobodies might become an alternative for immunotherapy to replace or complement convalescent plasma transfusion and equine hyperimmune serum. Nanobodies can be rapidly and cost-effectively produced in an active form in prokaryotic systems, and in addition the lack of an Fc domain reduces the possibility of undesired immunostimulatory activity on the host.

Here, we characterize the affinity properties of novel Nanobodies against the Spike protein of SARS-CoV-2. We demonstrate that the Nanobody W25 can be suitable as a diagnostic reagent and show that it is able to sensitively detect Spike by immunofluorescence in human cells as well as for direct Spike determination by ELISA Assays. The yield of production of W25 is high (~ 60mg/L in bacterial culture) as shown in Figure 2d and therefore inexpensive. Using fast thermal denaturation, we show that W25 interacts with the Spike RBD. We further determined by Thus, to date the neutralizing monomeric W25 Nanobody reported here shows the highest affinity for the RBD Spike protein of SARS-CoV-2. We have also demonstrated efficient neutralization mediated by W25 against clinical isolates of live viruses. An early isolate, similar to the original virus found in Wuhan, was neutralized by the W25 monomeric nanobody with an IC50 ~9.28 nM.

Interestingly a slightly enhanced neutralization effect was observed against the currently dominant SARS-CoV-2 variant G614, with an IC50 of ~5.09 nM. As residue 614 is outside the RBD, this finding may suggest differential RBD exposure between the two strains, which could underpin the observed selection for the G614 over time.

Animal testing for in vivo safety and efficacy in animals would be required to ascertain the therapeutic potential of W25. Our aim is to provide a stable, and scalable production of nanobody for the generation of a neutralizing inhaler able to block the viral replication directly in the upper airway in the early stages of the Covid-19 development. Nanobodies have been used previously with the same approach to treat syncytial virus infection (RSV). Successful preclinical and clinical trials have been performed indicating that 6mg/kg has been a safe and efficient dose for RSV (66) (67) (68) (69) (70) . In this case, a monomeric Nanobody called Nb017 with a Kd of ~ 17.88 nM was trimerized to a drug called ALX-0171 increasing the binding affinity to RSV to a Kd of ~ 0.113 nM. Since W25 already shows strong neutralizing activity against two important clinical virus isolates as monomer, such approaches could directly enhance efficacy and delivery. Interestingly, a recent study reported that the more prevalent virus variant G614 is associated with higher levels of viral nucleic acid in the upper respiratory tract in human patients, potentially making it even more accessible for inhaler delivery (24) .

The alpaca immunization process followed the guidelines established by the Bioethics Committee of the Austral University of Chile (certifications 338/2019 and 388/2020). One day before immunization, 5 mL of blood was collected for pre-immune serum tests. For immunization (day 1), 100 µg of full-length Spike protein of SARS-CoV-2 (SINOBiological) was used. The cold 

The selected VHH cDNA fragments were digested with SfiI and NotI restriction enzymes (Thermo Scientific) and ligated into the same sites of the purified vector pHen6 (72) . For periplasmic expression the E. coli wk6 strain was used. The pHen6-W25 vector was transformed and a single clone was selected from the agar plates and inoculated in 20 mL of liquid LB-medium containing 100μg/ml ampicillin and 1% glucose. The bacteria were cultured at 37 °C with agitation for 16 h.

The bacteria were then diluted into 1L Terrific Broth (TB) medium containing 100μg/ml ampicillin, 

The binding of W25 and the structural integrity of Spike RBD was verified using a label-free thermal shift assay with Tycho NT.6 (Nanotemper Technologies GmbH) using intrinsic tryptophan and tyrosine fluorescence. 10 µL solutions of Spike RBD (2 µM), W25 (2 µM) and Spike RBD mixed with W25 (2 µM each) were prepared and loaded into Capillaries Tycho NT.6 (TY-C001, NanoTemper Technologies GmbH). The Tycho instrument applied a quick thermal ramp from 35°C to 95°C with a heating rate of 30°C/min and the unfolding of proteins were monitored through changes in the 350 nm / 330 nm fluorescence emission ratio. Recombinant SARS-CoV-2 (2019-nCoV) Spike S1 Protein (RBD) from Trenzyme, Germany was used for the assays.

The dissociation constant (Kd) between the W25 Nanobody and SARS-CoV-2 S1 of Spike RBD The neutralizing antibody titers were defined as the amount of antibody (nM) resulting in a 50% reduction relative to the total number of plaques counted without antibody.

Immunization 

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Initial success in the identification and management of the coronavirus disease 2019 (COVID-19) indicates human-to-human transmission in Wuhan, China

SARS-CoV-2 detection in patients with influenza-like illness

Coronavirus Disease (COVID-19) Situation Report-103. World Health Organization

Public Health Interventions for COVID-19: Emerging Evidence and Implications for an Evolving Public Health Crisis

Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China

The Genome sequence of the SARS-associated coronavirus

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A new coronavirus associated with human respiratory disease in China

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

Structure of the SARS-CoV-2 spike receptorbinding domain bound to the ACE2 receptor

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection

Structure of the SARS-CoV-2 spike receptorbinding domain bound to the ACE2 receptor

Structural basis of receptor recognition by SARS-CoV-2

Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

The protein expression profile of ACE2 in human tissues

SARS-CoV-2 productively infects human gut enterocytes

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide

27. Fernández A. Structural Impact of Mutation D614G in SARS-CoV-2 Spike Protein: Enhanced Infectivity and Therapeutic Opportunity

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity

A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants

Zheng M, Song L. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV

Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection

A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Identification of Human Single-Domain Antibodies against SARS-CoV-2

Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold

Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies

Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus

Origin and evolution of the adaptive immune system: genetic events and selective pressures

Nanobodies: natural single-domain antibodies

Efficient cancer therapy with a nanobody-based conjugate

Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor

Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis

Selection and identification of single domain antibody fragments from camel heavy-chain antibodies

Single-domain antibody fragments with high conformational stability

Antiferritin single-chain Fv fragment is a functional protein with properties of a partially structured state: comparison with the completely folded V(L) domain

Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies

Construction of High-Quality Camel Immune Antibody Libraries

Escherichia coli surface display for the selection of nanobodies

Programming controlled adhesion of E. coli to target surfaces, cells, and tumors with synthetic adhesins

High affinity nanobodies against human epidermal growth factor receptor selected on cells by E. coli display

Selection of single domain antibodies from immune libraries displayed on the surface of E. coli cells with two beta-domains of opposite topologies

Characterization of nanobodies binding human fibrinogen selected by E. coli display

Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels

Analysis of the genome sequence of an alpaca coronavirus

Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein

Treatment for emerging viruses: Convalescent plasma and COVID-19

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Convalescent plasma in Covid-19: Possible mechanisms of action

Development of a hyperimmune equine serum therapy for COVID-19 in Argentina

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

Nanobodies(R) as inhaled biotherapeutics for lung diseases

Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection

Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs

Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures

Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs

Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies

The authors would like to thank the KOICID for partially supporting this study. We thank Dr. Ronald T. Hay for his generous support and assistance. This work was funded by FONDECYT No.